IP Flash


Steven M. Zeman, Ph.D., Dr. Franz-Josef Zimmer, European Patent Attorneys at Grünecker Patent- und Rechtsanwälte, Munich

On April 1, 2010 new rules for divisional applications came into force in the EPO. In the past one could file a “divisional” at any time during an application’s pendency. The new rules set limits on when and why divisionals may be filed. Applicants of older applications for which the new deadlines had already expired were given a final grace period to file all “voluntary” divisionals (more on these below…). This grace period ended on October 1, 2010 and triggered a flood of new divisionals in the EPO. With this flood just past, when and why may European divisionals now be filed?
As in the past, in order to be admissible, the divisional’s parent must still be pending when the divisional is filed. When an application is granted, it remains pending up to (but not in­cluding) publication of the grant. When an application is refused, it remains pending throughout the following

appeal period, even if no appeal is filed.
The old law knew only one type of divisional, but the new rules distinguish two types : voluntary and mandatory divisionals. “Voluntary” divisionals may be filed for any reason; “mandatory“ divisionals may only be filed in response to a unity objection. All voluntary divisionals must be filed within 24 months of the first communication of the EPO Examining Division (ED) in any earlier family member. Mandatory divisionals must be filed within 24 months of the ED’s communication in which it first raises a particular unity objection. Different unity objections trigger separate 24-month time limits when the objections are raised at different times.
In most cases, the “Communication of the Examining Division“ mentioned in the new rules will normally be an examination report under Art. 94(3) EPC. EPO search reports will not trigger time limits for divisionals (search reports are not prepared by the ED). Nor will an action issued by the EPO acting as a search or examination authority for an international (PCT) application.
To prevent loss of subject matter, applicants should note the 24 month time period from the first ED communication (time limit for filing voluntary divisionals). One should also carefully check each communication from the ED for any new unity objections, noting a separate 24 month time limit for each objection and requesting written clarification if necessary. The EPO’s “10-day-rule” for fictional notification of documents applies for the calculation of the 24 month time limits. Keeping careful track of these dates should help avoid loss of subject matter as a result of the EPO’s new legislation.



Saarbruecken – For a decade, stem cell researchers have tried to unravel how epi­gentic reprogramming works at the molecular level. Now, German researchers have discovered how the epigenetic code in the paternal part of the...



Cologne – Insulin resistance represents a key process in the development of diabetes II, which has reached epidemic proportions in industrial nations. Researchers from TaconicArtemis Pharmaceuticals and from the University of...



Martinsried-based Scil Technology has named its former CFO Christian Nafe as new Managing Director of the company. Nafe takes over from Dr. Weishui Weiser, who retires after five years at this post. It is the second time Nafe...



Hamburg-based Evotec AG is to expand its drug discovery capacity with a EUR12m acquisition. Yesterday, the company announced the purchase of private chemical proteomics specialist Kinaxo Biotechnologies GmbH. The transaction,...



Munich – For the first time, researchers have provided evidence that mRNAs can be used as drugs. By repairing genetic defects in knock-out mice, a team under Carsten Rudoph from Ludwig-Maximilians University in Munich...



Berlin – German bioengineers have grown the world’s first hair follicle from autologous stem cells in vitro. Lead investigator Roland Lauster (TU Berlin) said the discovery will speed up research on the causes of baldness, but...



Berlin – In the second major biotech-related funding project from the German Federal Ministry of Education and Research (BMBF) within two months, the ministry announced that Germany will be spending more than EUR5.5bn on a...



Munich – MorphoSys AG had a busy end of the year, announcing the achievement of clinical milestones four, five, six and seven from previous collaborations and a new cooperation agreement with Pfizer. This is a direct result of...



Berlin – German researchers have identified a completely new target for blood pressure regulation in the liver of mice. In yesterday’s issue of Neuron (69 (2) pp. 332-344) the team headed by Friedrich Luft (MDC Berlin) and...

Displaying results 51 to 60 out of 454

< Previous 51-60 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%


  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA98.85 CHF2421.7%
  • CYTOS1.01 CHF621.4%
  • WILEX3.59 EUR322.4%


  • MOLOGEN5.07 EUR-55.0%
  • BIOFRONTERA2.41 EUR-26.5%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015

Current issue

All issues